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This work focuses on two examples of randomized control trials- a set of Phase II
and Phase III clinical trials evaluating pre-exposure prophylaxis for HIV prevention
and a cluster randomized trial assessing a community engagement intervention de-
veloped to improve health outcomes in Baltimore. We discuss the unique statistical
challenges each trial raises, and we present our application of different methods
that address them. We conclude by discussing the commonalities between the
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Randomized controlled trials have long been considered the “gold standard” for
evaluating the effect of an exposure on an outcome of interest. The particularities
of a trial design depend upon the questions the trial seeks to address, but, broadly
speaking, either individuals or clusters of individuals are randomized to treatment
groups. One (or more) treatment group serves as the control (or comparison); study
participants in that group receive either a placebo, a standard-of-care treatment,
or no intervention, depending upon the context. With proper implementation,
participants are allocated to treatment groups in such a way that the groups vary
only by their exposure, preventing selection bias. However, study participants
may not receive the treatment to which they were assigned, or, treatment may
be received at inconsistent levels within a study arm, for a number of reasons
including low or non-adherence, treatment discontinuation due to study protocol,
study dropout, or spillover between different treatment arms. These potential
problems can all bias estimates of the treatment effect if not properly accounted for.
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This thesis is centered around a collection of randomized control trials. In
Chapter 2 and Chapter 3, we analyze of several clinical trials designed to assess the
efficacy of pre-exposure prophylaxis (PrEP) for HIV prevention. In Chapter 4, we
present the design and analysis of a cluster randomized trial that was part of the
broader Baltimore Community Organizations Neighborhood Network: Enhancing
Capacity Together (CONNECT) partnership (Wu, 2018). In the remainder of this
chapter, we provide background for the two applications and summarize our main
contributions to each. In Chapters 2 to 4, we provide the details of our analyses.
Finally, we conclude in Chapter 5 with a discussion of the connections between the
two projects and future directions for our work.
1.1 Background
1.1.1 Pre-Exposure Prophylaxis for HIV Prevention
Pre-exposure prophylaxis (PrEP) using the antiretroviral drugs tenofovir disoproxil
fumarate (TDF) alone or in combination with emtricitabine (FTC) is a growing
strategy to prevent HIV infection worldwide. Since 2015, the World Health Or-
ganization has recommended oral PrEP for all populations at “substantial risk”
of HIV infection (World Health Organization, 2015). In addition to oral dosing
of PrEP (either TDF alone or the combination TDF/FTC), vaginal gel containing
tenofovir has been recognized as an important method of preventing HIV infection
in women.
Placebo controlled, randomized clinical trials assessing the efficacy of PrEP, in
2
both oral and topical formulations, have had varying results. A number of trials
have demonstrated a high protective effect of daily oral PrEP among the following
at-risk populations: heterosexual couples where one partner is HIV positive and
the other negative in Kenya and Uganda (Baeten et al., 2012); men who have sex
with men in Peru, Ecuador, Brazil, the United States, South Africa and Thailand
(Grant et al., 2010); injection drug users in Thailand (Choopanya et al., 2013); and
heterosexual men and women in Botswana (Thigpen et al., 2012). Several trials
have found “on-demand PrEP,” wherein drug is administered both shortly before
and after sex, to be effective in preventing HIV infection. These studies have
focused on tenofovir gel taken among South African women (Karim et al., 2010)
and oral TDF/FTC among men who have sex with men (Molina et al., 2015).
In contrast, two studies of African women concluded no protective effect of PrEP.
The first, FEM-PrEP, evaluated oral PrEP in South Africa, Kenya and Tanzania (Van
Damme et al., 2012). The second, VOICE, included both oral and gel formulations
in South Africa, Uganda, and Zimbabwe (Marrazzo et al., 2015). In both studies
one or more treatment arms were stopped early due to futility. Low adherence to
assigned study products is thought to be a large contributor as to why the studies
failed to conclude any effectiveness of PrEP (Corneli et al., 2014; van der Straten
et al., 2014; Dai et al., 2015).
Beyond clinical trials, PrEP implementation and effectiveness has been evalu-
ated in a number of pragmatic trials. These include open-label extensions of many
of the phase II and III clinical trials described above (Grant et al., 2014; Baeten et al.,
2016). Additional demonstration projects, many of which are ongoing or planned,
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have focused on PrEP use in transgender women and men who have sex with men
(Hosek et al., 2013; Cohen et al., 2015; McCormack et al., 2016; Hojilla et al., 2016;
Hosek et al., 2017; Mahon, 2018), female sex workers (Kyongo et al., 2016; Cowan
et al., 2016), and adolescent girls and young women (Celum et al., 2015; Cowan
et al., 2016; EMPOWER Consortium Demonstration Project 2016; USAID Announces
Microbicide Awards 2016). An ongoing challenge in PrEP implementation is to un-
derstand which PrEP drug formulations and dosing strategies provide sufficiently
high protection against HIV infection in a broad range of at-risk populations.
1.1.2 Baltimore Community Organizations Neighborhood Network:
Enhancing Capacity Together (CONNECT) partnership
The second application, although focused upon improving health quality in Bal-
timore, Maryland, is rooted in global health delivery. The Baltimore CONNECT
partnership was developed using the World Health Organization’s African Partner-
ships for Patient Safety Community Engagement (ACE) Approach (Syed et al., 2009;
Ibe et al., 2018; Wu, 2018). Adopting the ACE framework, the goal of the study
was to bridge existing social and medical services, between community-based
organizations (CBOs) in East Baltimore and The Johns Hopkins Health System
(JHHS) (Ibe et al., 2018). By facilitating referrals both between CBOs and between
CBOs and the JHHS, the study sought to improve the health of East Baltimore
residents, in particular those identified as at high-risk for hospitalization or trips to
the emergency room. The details of the study framework, grounded in the concept
of “reverse innovation,” are given in Ibe et al. (2018).
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1.2 Contributions
Despite the many clinical trials assessing the efficacy of PrEP, much uncertainty
remains about the relationship between drug concentration in blood plasma and
the reduction in HIV risk. Key challenges in estimating this relationship include the
following: data on drug concentrations are relatively sparse and are collected via
case-control or case-cohort sampling within the active treatment arm(s); adherence
to assigned study drug may vary by study visit; and participants may miss study
visits or be lost to follow up. To address these challenges, we apply targeted
maximum likelihood estimation (TMLE) (Van der Laan and Rubin, 2006; Rose and
van der Laan, 2011; Van der Laan and Gruber, 2012) to estimate the protective
effect of drug concentration against HIV infection using longitudinal data from
two randomized, placebo-controlled clinical trials of daily PrEP: Partners PrEP
and VOICE. In Chapter 2 we present analyses using raw, measured concentration
data. We extend our analysis in Chapter 3 by integrating pharmacokinetic models
developed by Vucicevic, Savic, and Hendrix (In Preparation, 2018) using data from
the same set of clinical trials.
In Chapter 4, we describe the design, implementation, and analysis of a cluster
randomized trial with three key features: 1) constrained randomization to balance
groups on key baseline variables, 2) randomization inference to handle a relatively
small number of clusters with potential spillover between them, and 3) adjustment
for prognostic baseline variables that were not included in 1) so as to improve
precision. Despite the potential benefits of these three techniques, to the best of our
5
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Estimating the Protective Effect of
Longitudinal Drug Concentration in
Pre-Exposure Prophylaxis for HIV
Prevention
Reproduced with permission from:
Ruberman, Claire F., Jon A. Steingrimsson, Craig W. Hendrix, and Michael
Rosenblum (2018). “Estimating the Protective Effect of Longitudinal Drug Concen-
tration in Pre-Exposure Prophylaxis for HIV Prevention.” In preparation.
2.1 Introduction
Pre-exposure prophylaxis (PrEP) using the antiretroviral drugs tenofovir disoproxil
fumarate (TDF) alone or in combination with emtricitabine (FTC) is a growing
strategy for preventing HIV infection in vulnerable populations. In 2015, the World
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Health Organization recommended that PrEP be used by all individuals at high
risk of HIV infection as part of a comprehensive prevention strategy (World Health
Organization, 2015). Large PrEP evaluation and demonstration projects have been
and continue to be implemented worldwide (Krakower and Mayer, 2015; Baeten
et al., 2016a; Lal et al., 2017; Hoagland et al., 2017). Clinical trials evaluating the
prevention effect of PrEP have had varying, though mostly positive, results (Van
der Straten et al., 2012; Baeten and Grant, 2013; Fonner et al., 2016; Spinner et al.,
2016).
We focus on the following two randomized, placebo-controlled clinical trials of
daily PrEP: The Partners Preexposure Prophylaxis (PrEP) Study (Baeten et al., 2012)
and Vaginal and Oral Interventions to Control the Epidemic (VOICE) (Marrazzo et
al., 2015). Both trials evaluate oral TDF and/or combination TDF/FTC in prevent-
ing HIV seroconversion. The VOICE study also includes a tenofovir-containing
vaginal microbicide gel treatment arm. The Partners PrEP trial demonstrated
effectiveness of PrEP based on intention to treat analyses, reporting relative risk
reductions (one minus relative risk) of 67% (95% confidence interval: 44% to 81%)
and 75% (95% CI: 55% to 87%) in the TDF and TDF/FTC arms, respectively, com-
pared to the placebo arm (Baeten et al., 2012). In contrast, the VOICE trial reported
a relative risk reduction in the harmful direction of −4.4% (95% CI: −49% to 27%)
for the oral TDF/FTC arm. Both the oral TDF and tenofovir gel arms were stopped
early for futility with estimated relative risk reductions of −49% (95% CI: -129%
to -3%) and 15% (95% CI: -21% to 39%), respectively (Marrazzo et al., 2015). The
differences in PrEP effectiveness across trials have received substantial interest and
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have partially been attributed to differences in medication adherence, population,
and mode of transmission (Van der Straten et al., 2012; Dai et al., 2015).
We estimate the protective effect of setting plasma drug concentrations of
tenofovir above or below different thresholds over a period of eighteen months.
Learning about these effects may help inform the formulation of effective dosage
strategies for PrEP. It may also help determine when an adherence intervention is
needed to boost drug concentrations to a protective level. Identifying a threshold
for protective concentration levels may also be useful in setting target concentra-
tions for new modes of PrEP delivery, such as tenofovir gel rectal microbicides
(McGowan, 2014), dapivirine based vaginal rings (Baeten et al., 2016b), and long-
acting injectable formulations of antiretroviral drugs (Margolis et al., 2017).
Our analyses focus on substudies within the active treatment arms (the oral
TDF and TDF/FTC arms of Partners PrEP and VOICE and the 1% tenofovir gel
arm of VOICE), in which PrEP drug concentrations were measured from stored
plasma samples. In both studies, plasma samples were taken quarterly from every
study participant and stored. Additionally samples were taken and stored for
all cases at their time of seroconversion. Study participants were selected for
the concentration substudies through case-cohort designs. In each of the active
treatment arms, plasma concentrations were analyzed from the stored samples
at multiple visits for all participants who seroconverted (cases) up through the
visit where seroconversion was detected. Concentrations were also measured from
a randomly selected subset of participants (cohort) at the same set of visits until
dropout or study termination. In the Partners PrEP substudy, plasma samples from
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the 1, 3, and 6 month visits and every 6 months thereafter were assayed. All of the
plasma samples from the VOICE substudy were assayed. We analyze the Partners
PrEP and VOICE studies separately, but in each study we treat the oral TDF and
TDF/FTC arms as a single arm in our analyses because the dose of TDF given in
each arm was the same (at 300 mg daily).
Recent work has estimated the causal effect of drug plasma concentration using
data from the above trials, including Dai et al. (2013) and Murnane et al. (2015).
These analyses infer the protective effect of assignment to PrEP among the group
of participants who would have a specified level of drug concentration (at either
a fixed study visit or at any study visit) if assigned to one of the active arms. We
use the longitudinal TMLE of Van der Laan and Gruber (2012) to estimate the
protective effect against HIV infection of setting plasma drug concentration levels
to be above the limit of quantification (0.31 ng/mL) at each of the 6, 12, and 18
month study visits. Rather than using one measure to characterize a participant’s
concentration level throughout the study, our analyses incorporate time-varying
concentration levels for study participants.
We account for reported instances of unprotected sex as a potential time-varying
confounder of the relationship between drug concentration and risk of HIV infec-
tion. Golub, Operario, and Gorbach (2010), Liu et al. (2013), and Calabrese and
Underhill (2015) found suggestive evidence of such an association; they identified
groups of individuals who adhere to PrEP regimens and do not partake in high
risk behaviors. Additionally, decreases were observed in self-reported sexual risk
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behaviors over the course of the Partners PrEP trial (Baeten et al., 2012). Further-
more, there was evidence in the VOICE study that levels of medication adherence
may have changed over time (Van der Straten et al., 2014).
Bias due to time-dependent confounding cannot generally be removed by sim-
ple regression adjustment (Hernán, Brumback, and Robins, 2000). The longitudinal
TMLE analysis accounts for measured, time-varying confounders. The longitudi-
nal TMLE also accounts for informative censoring. It builds upon ideas from Van
der Laan and Rubin (2006), the sequential regression estimators of Robins (2000)
and Bang and Robins (2005), and the general semiparametric efficiency theory of
Robins and Rotnitzky, 1992. The assumptions are discussed in Section 4.2.
We implement our analyses using the LTMLE (Longitudinal TMLE) R package
(Schwab et al., 2016). We apply weighting techniques from Rose and van der Laan
(2011) to account for the concentration substudy designs. Longitudinal TMLE has
previously been used to analyze the causal effects of, for example, antiretroviral
therapies on drug resistance and survival among HIV-infected patients (Stitelman,
De Gruttola, and van der Laan, 2012), warfarin on stroke or death (Brooks et al.,
2013), hepatitis C virus clearance on end-stage liver-disease free survival (Schnitzer
et al., 2014b), breastfeeding on gastrointestinal infection in infants (Schnitzer et al.,
2014a), early interventions on preventing child obesity (Decker et al., 2014), and
task shifting with HIV treatment programs on patient outcomes in East Africa
(Tran et al., 2016). Rose (2011) applied the method of Rose and van der Laan (2011)
in conjunction with the superlearner machine learning algorithm to estimate a
regression function. However, the quantity estimated was not a causal effect as
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is the goal of our estimation problem, which has additional challenges such as
handling time-dependent confounding. To the best of our knowledge, this is the
first application of the Rose and van der Laan (2011) method to estimate a causal
effect. This is also the first application to combine this method with the longitudinal
TMLE of Van der Laan and Gruber (2012).
Section 2.2 describes the two PrEP trials. Section 2.3 details the structure of the
data and our target of estimation, and Section 4.2 discusses the TMLE procedure for
estimating longitudinal effects of plasma concentration on HIV risk using data from
case-cohort substudies. Our results from the two trials and comparisons to previous
results are given in Section 2.5. Limitations of our methods and potential reasons
for differences between our results and those from related work are discussed in
Section 2.6.
2.2 Two Pre-Exposure Prophylaxis Randomized Trials
Partners PrEP was a phase III, randomized, double-blinded, placebo-controlled
trial that assessed the use of daily oral TDF or TDF/FTC to prevent HIV infection
among 4747 heterosexual serodiscordant couples (one HIV positive the other HIV
negative) in Kenya and Uganda (Baeten et al., 2012). Beginning in 2009 and lasting
through 2011, the HIV negative partner from each couple was randomized to one
of daily oral TDF, TDF/FTC, or placebo and followed monthly for three years or
until seroconversion. We restrict our attention to a case-control study consisting of
17 and 13 cases in the TDF and FTC/TDF arms and a randomly selected cohort
of 200 participants (100 from each arm), for whom plasma concentrations were
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measured. Two of the study participants selected into the cohort seroconverted
over the course of the study and two more were lost to followup. Additionally, one
case in the FTC/TDF arm, who seroconverted at 23 months, did not have plasma
samples available and was excluded from the analysis.
The VOICE study was a phase IIB, randomized, placebo-controlled assessing
daily oral TDF, oral TDF/FTC, or tenofovir 1% vaginal gel among 5029 heterosexual
women in South Africa, Uganda, and Zimbabwe. The primary endpoint was HIV-
1 infection, with HIV testing performed monthly (Marrazzo et al., 2015). The
study began in September 2009 and continued to enroll women through June 2011.
Although follow-up was planned until June 2012, the Data and Safety Monitoring
Board (DSMB) determined on September 16, 2011 that oral TDF tablets were
safe but not effective in VOICE and recommended discontinuing their use (MTN
Statement on Decision to Discontinue Use of Oral Tenofovir Tablets in VOICE, a Major
HIV Prevention Study in Women 2011). The DSMB made a similar determination
for tenofovir gel on November 17, 2011 (MTN Statement on Decision to Discontinue
Use of Tenofovir Gel in VOICE, a Major HIV Prevention Study in Women 2011). We
analyze data from a case-cohort concentration substudy within the oral TDF, oral
TDF/FTC, and TFV gel arms consisting all seroconverters who do not have acute
HIV infection at enrollment and returned for at least one visit in the six months
after enrollment and a randomly sampled cohort. There were 741 participants
in the case-cohort substudy assigned to either oral TDF or oral TDF/FTC, 113 of
whom were cases. Additionally, there were 669 participants in the case-cohort
substudy assigned to the TFV gel arm, including 61 seroconverters.
18
We restricted our analyses to the first 18 months of each study due to data
sparsity at later visits. Only 3 of the 29 seroconversions in the Partners PrEP
analysis data and 3 of 113 seroconversions in the VOICE analysis data occurred
after 18 months. The median follow-up times for participants in the substudies
were 18 and 13 months for Partners PrEP and VOICE, respectfully, so we considered
the 18 month cutoff to be reasonable. Similar adjustments for sparsity are made
when analyzing the effect of hepatitis C virus clearance using longitudinal TMLE
in Schnitzer et al. (2014b). We included baseline data and semiannual concentration
measurements in our analyses.
2.3 Longitudinal Data Structure and Target of Estima-
tion
We analyzed concentrations measured from the 6, 12, and 18 month study visits. If a
study participant missed one of these semiannual visits, we used, if available, their
plasma concentration measurement from the visit three months prior. Participants
who missed a semiannual visit and did not have a concentration measurement
from the three months prior were right censored.
Our analyses use the longitudinal TMLE of Van der Laan and Gruber (2012)
with case-cohort weighting as in Rose and van der Laan (2011), which we describe
below. For each participant we observe a vector of baseline variables W. Visits
after baseline are coded as j = 1, 2, and 3, representing the 6 month, 12 month, and
18 month visits, respectively. Each observation at visit j consists of an indicator of
censoring, Cj, and, if the participant has not been censored by that visit, an indicator,
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Aj, that plasma concentration exceeds a threshold, an indicator, Lj, of reported
unprotected sex in the six months prior, and an indicator, Yj, that the participant is
HIV positive. We specify the following data ordering for each participant, which
reflects the time ordering by visit:
(W, L1, A1, Y1, C2, L2, A2, Y2, C3, L3, A3, Y3).
Note that setting concentration to follow a certain regimen may potentially
affect time dependent covariates. For example a participant may be less likely to
have unprotected sex if they do not take the drug.
Using the potential outcomes framework described in Rubin (1974) let Y(ā)
denote a study participant’s HIV status (not necessarily observed) at 18 months
were they to attend their 6, 12, and 18 month study visits and follow treatment
regimen ā. For example, Y(ā=1̄) and Y(ā=0̄) correspond to the participant’s HIV
statuses had their concentrations at each of their 6, 12, and 18 month study visits
been maintained above and below the fixed threshold, respectively.
We define and compare the probability of seroconversion by 18 months under
two treatment regimens: maintaining a plasma tenofovir concentration above or
below a threshold at every visit (up to the final visit or until seroconversion is
detected, whichever happens first) except for visits where drug was contraindicted
due to safety concerns arising from pregnancy, breast-feeding, or laboratory abnor-
malities (Baeten et al., 2012). We estimate the marginal probability P(Y(ā) = 1) of
seroconversion by 18 months in the treatment arm setting a treatment regimen ā
of above or below a concentration threshold throughout the study (Van der Laan
20
and Gruber, 2011; Van der Laan and Gruber, 2012). This estimand differs from
the target of estimation in principal stratification analysis by Dai et al. (2015): the
average causal effect among compliers (the population whose concentration would
exceed a threshold if assigned to the treatment arm). In contrast, our estimand is
for the whole treatment arm population.
We use the limit of tenofovir quantification, 0.31 ng/mL, as our concentration
threshold in these analyses. Table 2.1 describes how many participants in our
data sets followed either of the two regimens described above. This is important
because if few participants follow a given regimen, then it is more challenging to
reliably estimate the corresponding probabilities P(Y(ā)). Study participants were
right censored if more than six months passed between study visits. A relatively
small percentage of participants followed either treatment regimen in its entirety.
The meaning of setting concentration above the limit of quantification depends
on the distribution of concentration measurements conditioned on being above
this limit and on the observed history. In particular, setting concentration to above
the limit of quantification means setting concentration to a random draw from this
conditional distribution. Though we are not able to give plots of this conditional
distribution (which involves multiple variables and would difficult to display), we
present the marginal distributions of the observed concentrations in the Partners
PrEP oral, VOICE oral, and VOICE gel arms in Figure 2.1. The distributions of
quantifiable concentrations (74% of the observed concentrations in Partners PrEP
and 28% and 20% of concentration measurements in the VOICE the oral and gel
arms, respectively) differ by study. Quantifiable concentration levels were highest
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in the Partners PrEP oral arms, with a mean (median) of 93 ng/mL (81 ng/mL),
as compared to 75 ng/mL (63 ng/mL) in the VOICE oral arms and 2 ng/mL (1
ng/mL) in the VOICE gel arm. The differences in concentrations observed in the
VOICE oral and gel arms are consistent with pharmacokinetic studies examining
different routes of dosing (Hendrix et al., 2013).
2.4 Targeted Maximum Likelihood Estimation for Lon-
gitudinal Data Structures in Nested Case-Cohort
and Case-Control Studies.
Assumptions are needed in order to identify the parameter P(Y(ā) = 1) i.e., the
probability of seroconversion by 18 months if all participants were set to follow ā.
We make the following assumptions:
• Consistency: A participant’s potential outcome under their observed plasma
drug concentration history is their observed outcome.
• Positivity: At every visit, given any participant’s covariate history up to that
visit, a participant has a positive probability of continuing to follow a given
treatment regimen.
• Time ordering: Each variable does not have a causal effect on those measured
before.
• I.I.D. data: Each participant’s longitudinal data vector (from Section 2.3) is an
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independent, identically distributed draw from an unknown joint distribu-
tion P.
• No unmeasured confounders: There are no variables missing from the analy-
sis that affect both (i) censoring and/or plasma drug concentration and (ii)
seroconversion.
For a detailed description of the aforementioned assumptions see Stitelman,
De Gruttola, and van der Laan (2012). As part of the time ordering assumption, we
assume that a participant’s concentration measurement at a given semiannual visits
is representative of their drug concentration over the last six months. Additionally,
in order to apply the two-stage sampling method of Rose and van der Laan (2011),
we make the assumption that all study participants who seroconverted and were
not lost to follow-up by 18 months are included as cases and that each cohort is a
simple random sample of the remaining participants. This holds by design.
Fitting the TMLE estimator requires specifying models for censoring, drug
concentration, time dependent covariates and seroconversion at each visit. All
models used for the TMLE were main effects logistic regression models. In the
Partners PrEP study, we adjusted for age and gender as baseline variables. In the
VOICE study, we adjusted for age, marital status, and HSV-2 status as baseline
variables. In both studies, we also adjusted for reported unprotected sex during
the six months prior to each study visit as a potential time dependent confounder.
These variables were selected because they were associated with plasma concen-
tration levels and/or risk of seroconversion (Kiser et al., 2008; Haberer et al., 2013;
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Donnell et al., 2014; Murnane et al., 2015; Burns, Hendrix, and Chaturvedula, 2015;
Lu et al., 2016). Event sparsity limited the number of baseline variables that we
were able to adjust for.
The TMLE estimator has several useful properties. The estimator is consistent
if either (1) the models for concentration and censoring are correct, or (2) both the
models for seroconversion and time dependent covariates are correct. This property
is referred to as double robustness. In contrast, the principal stratification methods
used in previous analyses are not doubly robust. In addition, if all the models
required for the implementation of the TMLE estimator are correctly specified the
estimator is asymptotically efficient (that is, has the smallest variance among a
large class of estimators). Finally, the TMLE estimator is a substitution estimator,
so it is guaranteed to produce estimators for probabilities that fall between zero
and one.
For nested two-stage sampling designs, Rose and van der Laan (2011) show that
incorporating appropriate weights to the TMLE fitting process leads to consistent
estimators of treatment effects that are doubly robust and locally efficient. The
weights are defined as the inverse probability of selection into the concentration
substudy given the data from the main study. All cases in oral TDF and TDF/FTC
arms are included in the concentration substudies, so all cases, even those who
seroconverted after 18 months, have a weight of 1. In the Partners PrEP, VOICE
oral, and VOICE gel substudies, the cohort weights are 15, 3, and 1.5, respectively.
Each weight is calculated as the ratio of the number of study participants in the
active treatment arm who test negative for HIV at all study visits or until censoring
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to the the number of study participants in the concentration substudy who test
negative for HIV at all study visits or until censoring.
2.5 Results
2.5.1 Estimates using Longitudinal TMLE
We present analyses of Partners PrEP and VOICE studies using the ltmle package
(Schwab et al., 2016) in R (R Core Team, 2015). We set the concentration threshold
used to define the regimens to be the limit of tenofovir plasma quantification,
which was 0.31 ng per milliliter. This concentration is consistent with oral dosing
within the last week (Donnell et al., 2014; Hendrix et al., 2016) and with gel dosing
within the last two to three days (Hendrix et al., 2013).
Table 2.2 presents the estimated HIV incidences (infections per 100 person-years)
in each of the Partners PrEP oral, VOICE oral, and VOICE gel arms under two
different concentration regimens. The relative risk reduction, (1 − relative risk)×
100%, quantifies the effectiveness against HIV infection of setting concentration
at the first three bi-annual visits to above the limit of quantification as compared
to below the limit of quantification. Each 95% confidence interval was calculated
using the bias-corrected and accelerated (BCa) bootstrap with 2, 000 bootstrap
replicates. The estimated probabilities of seroconversion vary between studies,
which was expected due to differing baseline risks among the study populations
(Hugonnet et al., 2002; Beyrer et al., 2012). In both studies, the estimates were
similar whether we adjusted for only baseline variables or for baseline variables
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and measures of time-varying risk. However, the confidence intervals for the
estimated incidences and relative risk reductions were much wider when adjusting
for time-varying risk. In the VOICE gel analysis, the confidence interval for the
relative risk reduction when setting concentration to be quantifiable does not
overlap zero when we adjust only for baseline variables; however, it does overlap
zero when we adjust for baseline variables and time-varying risk.
We also considered concentration thresholds of 10 and 40 ng/mL, consistent
with dosing in the last 2 to 3 days and 24 hours, respectively (Donnell et al.,
2014). In the Partners PrEP study, the results of our analyses were very similar
regardless of concentration threshold. It is likely that our analyses have low
power to distinguish between the effects of setting concentration to be quantifiable
versus setting concentration to be above 10 or 40 ng/mL because almost all of the
concentration measurements above the limit of quantification exceeded 40 ng/mL.
Of the quantifiable 381 concentration measurements in the Partners PrEP analysis,
only 19 (5%) were between 0.31 and 10 ng/mL, and only 38 (10%) were between 10
and 40 ng/mL.
In the VOICE analyses, when we used as thresholds 10 or 40 ng/mL, the boot-
strap procedure detected potential instability in the BCa confidence intervals. The
instability likely occurred because very few study participants, in particular cases,
maintained concentration regimens above the higher thresholds.As a consequence,
the results for VOICE at thresholds of 10 and 40 ng/mL may be unreliable, and we
do not report them.
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2.5.2 Comparisons to Previous Analyses
The results of the modified intention-to-treat (ITT) analyses, which compared the
risk of infections between different treatment arms after excluding study partici-
pants determined to be HIV positive at enrollment, are presented in Table 2.3. In
each of the Partners PrEP oral, VOICE oral, and VOICE gel analyses, our estimates
of the incidence setting concentration to consistently below the limit of quantifi-
cation were very similar to the observed HIV incidences in their corresponding
placebo arms. Figures 2.2, 2.3, and 2.4 compare estimates of the effectiveness of
PrEP between our longitudinal TMLE analyses, the modified ITT analyses, and
previous secondary analyses by Murnane et al. (2015) and Dai et al. (2015) for
the Partners PrEP and VOICE studies, respectively. We note that the target of
estimation and assumptions differ for each approach.
The primary Partners PrEP analysis, a modified ITT analysis, concluded that
treatment with TDF and TDF/FTC, as compared to placebo, conferred relative
reductions of HIV incidence, (1 − incidence rate ratio)× 100%, of 67% (95% CI:
44% to 81%) and 75% (95% CI: 55% to 87%), respectively (Baeten et al., 2012).
As a secondary analysis, Murnane et al. (2015) used principal stratification to
estimate the effect of PrEP on risk of HIV infection among “high adherers.” They
defined high adherers as those who, if assigned to TDF or TDF/FTC, would
achieve a plasma concentration level of PrEP above 40 ng/mL at their six month
visit. Using data from the concentration substudy, they built a logistic regression
model for the probability that a study participant is a high adherer. This model
was used to predict each study participant’s probability of high adherence. They
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used Cox regression with the following terms to estimate the effectiveness of
PrEP: randomization arm, the predicted probability of high adherence, and the
interaction between the two. Among the strata of high adherers, Murnane et al.
(2015) estimated a reduction in hazard of HIV acquisition by 81% (44% to 93%)
with TDF and 88% (48% to 97%) with TDF/FTC. Although the causal questions
differ between the longitudinal TMLE and principal stratification analyses, both
analyses concluded similar levels of PrEP effectiveness. We note that the above
principal stratification approach relies on the parametric prediction models for both
plasma drug concentration and risk of seroconversion being correctly specified.
The method also assumes that plasma drug concentration stays constant among
study participants between their 6 month visit and end of follow up (up to 36
months).
In the VOICE trial, the modified ITT analysis compared HIV incidence in each
of the treatment arms to their corresponding placebo arms using a proportional
hazards model stratified by site. The effectiveness of oral TDF, oral TDF/FTC, and
TFV gel, (1 − hazard ratio)× 100%, was estimated to be −49% (95% CI: −129 to
3%), −4.4% ( 95% CI:−49% to 27%), and 15% (95% CI:−21 to 39%), respectively
(Marrazzo et al., 2015). Additionally, Dai et al. (2015) used principal stratification
to estimate the effect of PrEP on the risk of HIV infection among adherers. They
defined adherers in two ways: first, as those with a quantifiable level of plasma
tenofovir in their three month sample; second, as those with a quantifiable level
of plasma tenofovir in at least one plasma sample during follow-up. For each
of the oral TDF, oral TDF/FTC, and gel arms, they used a weighted Poisson
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model to compare HIV incidence between adherers in the treatment arm and all
participants in the placebo arm, while adjusting for potential confounding. For the
first definition of adherer, Dai et al. (2015) estimated relative risk reductions of 2%
(95% CI: −71% to 43%), −2% (95% CI: −116% to 52%), and 47% (95% CI: 3% to 71%)
with assignment to oral TDF, oral TDF/FTC, and TFV gel arms, respectively. For
the second definition of adherer, Dai et al. (2015) estimated relative risk reductions
of −7% (95% CI: −142% to 53%), −26% (95% CI: −140% to 34%), and 60% (95% CI:
2% to 84%) with oral TDF, oral TDF/FTC, and TFV gel, respectively.
In contrast, using the longitudinal TMLE, we estimated the relative risk of
setting drug concentration to above the limit of quantification in the combined
VOICE oral TDF and TDF/FTC arms to be 42% (95% CI: −31% to 80%). In the
TFV gel arm we estimated a relative risk reduction of 88% (95% CI: −48% to 100%).
Unlike previous work, we accounted for varying levels of drug concentration over
time. Dai et al. (2015) used a homogeneous Markov chain model to estimate the
probability, given a quantifiable plasma concentration at one visit, of having plasma
concentration below the limit of quantification at the next visit. They estimated
non-negligible probabilities of 39% for the combined oral TDF and TDF/FTC
arms and 56% for the TFV gel arm, demonstrating that the assumption of plasma
concentration not changing over time was likely violated in the VOICE trial.
To highlight the importance of accounting for longitudinal concentration, we
compared the results from our analyses with a similar analysis using the longi-
tudinal TMLE method but with the assumption, made in previous analyses, that
concentration is constant over time. We repeated the longitudinal TMLE analysis
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after replacing the observed 12 and 18 month concentrations (for study partici-
pants who neither had been censored nor had seroconverted) with their 6 month
measurements. In the VOICE study, repeating the analysis using only concentra-
tion measurements from the 6 month study visit, we estimated in the oral arms
a −1% relative risk reduction (95% CI: −65% to 43%), which highly overlaps the
confidence intervals in Dai et al. (2015). In the gel arm, we estimated a much lower
relative risk reduction of 17% (95% CI: −127% to 79%) compared to that in the
original analysis (Figure 2.4). The estimated effectiveness using only the 6 month
concentration measurements was closer to the estimate by Dai et al. (2015) than
our original estimate.
In contrast, in the Partners PrEP study, the estimated relative risk reduction
changed very little (from 82% to 81%) when we used only the 6 month concentration
measurements (Figure 2.2). Our results for the Partners PrEP study are likely
consistent with previous analyses because most study participants maintained
fairly consistent concentration levels over time (Donnell et al., 2014). In contrast,
concentration measurements among individual study participants in both the
VOICE oral and gel arms varied considerably over the course of the study, typically
decreasing over time, as illustrated in Figure 2.5.
2.6 Discussion
We used TMLE to estimate the causal effect of setting plasma concentration mea-
sures to be consistently above a specified threshold on the risk of HIV infection in
the Partners PrEP and VOICE studies. We add to a growing body of research in
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this area by using targeted maximum likelihood estimation to account for the lon-
gitudinal nature of the data and correcting for potential time varying confounding.
We used weighting to account the for the case-cohort sampling schema for
concentration measurements. An alternative approach to account for the sampling
schema would be to use multiple imputation; however, this requires the imputation
model, in addition to the outcome model, to be correct. Additionally, imputation
requires the predictors of drug concentration levels, such as participant reported
adherence and counts of returned pills, to be accurate. These measures have been
found to be unreliable in several PrEP studies, including VOICE (Marrazzo et al.,
2015; Dai et al., 2015).
Our results for the Partners PrEP study are similar to previous analyses. Unlike
previous analyses, our point estimates from the combined oral arms of the VOICE
study are in the direction of benefit. We estimate a higher protective effect in the
VOICE gel arm than previous analyses. These differences are not surprising given
that the target parameters differ between these analyses and that we account for
time-varying levels of drug concentration. Additionally, unlike previous analyses
that considered the two oral arms separately, we estimated the effect of tenofovir
in the combined TDF and TDF/FTC oral arms in each of the Partners PrEP and
VOICE studies. All of our results are consistent with claims that sustaining high
concentration levels is a key factor in the potential success of any future PrEP trials.
As with previous analyses, caution must be taken with our results. As in
any analysis aimed at estimating causal effects from observational data, a causal
interpretation of the estimated parameters requires the strong assumptions listed
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in Section 4.2, including that of no unmeasured confounding. Several groups have
recently reported that bacteria associated with bacterial vaginosis, can metabolize
tenofovir by an, as yet, uncertain mechanism, resulting in lower concentrations
of tenfovir in cervicovaginal fluid and, likely, in tissue and plasma (Heffron et al.,
2017; Hillier et al., 2017; Klatt et al., 2017; Velloza and Heffron, 2017). This has
resulted in some loss of tenfovir’s protective effect in the CAPRISA 004 clinical
trial (Klatt et al., 2017; Velloza and Heffron, 2017). Because we do not know which,
if any, women in the Partners PREP or VOICE trials had bacterial vaginosis at the
time of plasma sampling, we cannot rule this out as an additional unmeasured
variable that may impact our findings. Additionally, there may be sources of
measurement error in the data, such as a white-coat effect, wherein concentration
levels increase just prior to a clinic visit since the participant knows he/she will
have concentration assessed. If there were a white-coat effect, then participant-
visits might be classified as exceeding the concentration threshold, even if they
were below the threshold for most of the time at risk between visits.
The main limitations in our longitudinal analyses were that the outcome, sero-
conversion, was rare and was (like blood concentration of drug) measured at visits
separated by multiple months. The problem of event sparsity was also present
when Schnitzer et al. (2014b) used longitudinal TMLE to estimate the causal effect
of hepatitis C virus clearance on end-stage liver disease free survival. They used
exposure and censoring models that depended only on baseline covariates and
those from the previous time point, rather than the full history and restricted the
followup period. Similarly, our exposure and censoring models depended only on
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covariates from the previous time point. We also restricted our analyses to the first
18 months of the study.
An important limitation in the VOICE analyses is that the majority of concen-
tration measurements (72% and 80% in the oral and gel arms, respectively) were
below the limit of quantification. As indicated in Table 2.1, there were very few
study participants who followed a high concentration regimen. In particular, in the
concentration substudy of the VOICE gel arm, only 11 of 669 participants followed
a quantifiable concentration regimen. As a result, these analyses extrapolate from
a small number of observations.
In Table 2.4 we compare self-reported risk behaviors over time between the 11
participants and the overall VOICE gel arm to investigate whether the participants
following a quantifiable concentration regimen were systematically less risky
then the rest of the study arm. If that were the case, the reduction in risk of
HIV infection we estimated from setting participants to follow a quantifiable
concentration regimen might be due to confounding by risk factors rather than
a biological protective effect of tenofovir. We do not observe any changes in risk
behavior over time, and behavior among the 11 study participants following the
quantifiable concentration regimen appears to be similar or slightly riskier to the
overall behavior in the VOICE gel arm.
We repeated our LTMLE analyses of the VOICE gel arm using data from only the
first 6 and 12 months of the study. Using data from the first 6 months, we estimated
the protective effect of setting plasma tenofovir concentration to quantifiable at the
6 month visit, and using data from the first 12 months, we estimated the protective
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effect of setting plasma tenofovir concentration to quantifiable at both the 6 and 12
month study visits. Although in practice we are interested in the protective effect
of maintaining drug concentrations over a longer period of time, these analyses
have the advantage that a larger number of study participants follow a quantifiable
concentration regimen when only considering concentration data from the first
6 or 12 months as compared to 18 months. As shown in Table 2.5, restricting our
analyses to the first 6 or 12 months increases the number of study participants
following a quantifiable concentration regimen to 148 and 31 study participants,
respectively. The results from the LTMLE analyses using data from only the first 6
and 12 months, presented in table 2.6 are qualitatively similar.
A final limitation is that our analyses of focus exclusively on estimating the
effect of plasma tenofovir concentration on risk of HIV infection. Serum concentra-
tions have been found to be considerably higher after oral dosing as compared to
vaginal gel dosing, (Hendrix et al., 2013) meaning detection of plasma tenofovir
from topical dosing requires a higher level of adherence than from oral dosing.
Consequently, the women following a quantifiable tenofovir regimen in the VOICE
gel arm are likely all highly adherent, while the women following a quantifiable
tenofovir regimen in the oral arms are a mixture of moderate and highly adherent
participants. Because moderately adherent participants in the VOICE gel arm may
have been classified as following a below tenofovir regimen, the true efficacy might
be higher than estimated for the topical dosing arm. In contrast, vaginal gel dosing
achieves much higher drug concentrations in vaginal tissue, an important site of
consideration for HIV infection, than oral dosing (Hendrix et al., 2013), achieving
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quantifiable levels of plasma tenofovir from oral and gel dosing likely has different
implications for both adherence levels and tenofovir concentrations in different
compartments relevant for HIV infection. In particular, when analyzing only
plasma concentration data, detection of tenofovir from topical dosing indicates a
higher level of adherence than oral dosing. As a result, the true efficacy might be
higher than estimated for the topical dosing arm.
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Figure 2.1: Distribution of plasma concentration measurements in the first 18 months by study. The limit
of quantification is 0.31 ng/mL for both studies. In Partners PrEP, 74% of concentration measurements were
above the limit of quantification. In the VOICE study, 28% and 20% of concentration measurements from the






































































































Estimated Protective Effect: Partners PrEP Oral Arms
Figure 2.2: Comparison of results analyzing the Partners PrEP study using the longi-
tudinal TMLE to results from previous methods. We compare the protective effect of
PrEP estimated by our longitudinal TMLE analyses (“LTMLE”), intention-to-treat analyses
(“ITT”), secondary analyses using concentration data by Murnane et al. (2015) (“Principal
Stratification”), and repeating our longitudinal TMLE analysis when we only use each
study participant’s 6 month concentration measurement (“LTMLE-6m Data”). All point





































































































Estimated Protective Effect: VOICE Oral Arms
Figure 2.3: Comparison of results analyzing the VOICE oral arms using the longitudi-
nal TMLE to results from previous methods. We compare the protective effect of PrEP
estimated by our longitudinal TMLE analyses (“LTMLE”), intention-to-treat analyses
(“ITT”), secondary analyses using concentration data by Dai et al. (2015) (“Principal Strati-
fication”), and repeating our longitudinal TMLE analysis when we only use each study
participant’s 6 month concentration measurement (“LTMLE-6m Data”). All point estimates























































Estimated Protective Effect: VOICE Gel Arm
Figure 2.4: Comparison of results analyzing the VOICE gel arm using the longitudinal
TMLE to results from previous methods. We compare the protective effect of PrEP esti-
mated by our longitudinal TMLE analyses (“LTMLE”), intention-to-treat analyses (“ITT”),
secondary analyses using concentration data by Dai et al. (2015) (“Principal Stratification”),
and repeating our longitudinal TMLE analysis when we only use each study participant’s
6 month concentration measurement (“LTMLE-6m Data”). All point estimates (dots) are
given with 95% confidence intervals (bars).
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VOICE Oral Tenofovir Concentrations by HIV Status
(a)
Case Cohort


























VOICE Gel Tenofovir Concentrations by HIV Status
(b)
Figure 2.5: Concentration measurements from the first three semi-annual visits by HIV status in the
VOICE gel and oral arms. Each line shows the 6, 12, and 18 month concentration measurement for an
individual study participant. Lines that end before 18 months are due to seroconversion, missed study visits,
or participant drop-out. Participants are separated by their HIV status at the end of the study. Concentration
levels vary considerably among individuals in both the VOICE oral (a) and gel (b) arms, typically with the
trend of decreasing concentrations over time.
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Partners PrEP VOICE Oral VOICE Gel
Quantifiable All 84 (37%) 45 (6%) 11 (2%)
Concentration HIV+ 8 (31%) 8 (7%) 2 (4%)
Regimen HIV- 76 (37%) 37 (6%) 9 (1%)
BLQ All 31 (14%) 257 (35%) 140 (21%)
Concentration HIV+ 12 (46%) 82 (75%) 42 (78%)
Regimen HIV- 19 (9%) 175 (28%) 98 (16%)
Switched All 19 (8%) 81 (11%) 55 (8%)
HIV+ 1 (4%) 17 (15%) 9 (17%)
HIV- 18 (9%) 64 (10%) 46 (7%)
Censored All 91 (40%) 358 (48%) 463 (69%)
HIV+ 5 (19%) 3 (3%) 1 (2%)
HIV- 86 (42%) 355 (56%) 462 (75%)
Total All 225 741 669
HIV+ 26 110 54
HIV- 204 634 616
Table 2.1: Number of concentration substudy participants in the Partners PrEP and
VOICE studies by treatment, concentration regimen followed, and seroconversion out-
come. Number and percent of concentration substudy participants in the Partners PrEP
and VOICE oral TDF and TDF/FTC and VOICE TFV gel arms who maintained quantifiable
or below quantifiable concentration levels over the first eighteen months of the study or
until serconversion, were censored at or before eighteen months, or switched between
concentration levels. Participants who did not follow a treatment regimen in its entirety
contributed to the analysis until they switched concentration groups or were right censored.
The first row, “Quantifiable Concentration Regimen," enumerates the number of study
participants who maintained quantifiable concentration levels at each of their 6, 12, and 18
month visits, or until serconversion. The second row, “BLQ Concentration Regimen," does
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This chapter extends the work of Chapter 2 by integrating pharmacokinetic models
into our causal analysis of the protective effect of PrEP drug concentration against
HIV infection. Treating output from the PK model, rather than raw concentration
levels, as the exposure allows us to account for both the time between a study
participant’s last PrEP dose and when their plasma sample was taken and the
known variability of drug concentrations in the body over time. The work in this
chapter largely supports the conclusions from Chapter 2, but it also allows us to
analyze the effect of sustaining higher levels of tenofovir drug concentration in
the VOICE oral arms than was possible using the raw concentration data. In the
remainder of this section, we provide background into pharmacokinetic modeling.
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In Section 3.2 we discuss the methods for modeling both PrEP drug concentrations
and their effect on the the the risk of HIV infection. In Section 3.3 we present our
results and compare them to the results from Chapter 2. We conclude in Section
3.4 with a discussion of ongoing and future areas of work.
Pharmacokinetics (PK) is the study of the behavior of a drug in the body over
time. Drug characteristics typically reported include absorption, distribution,
metabolism, and excretion (Nelson, 1961; Dudley, 1995; Zhang et al., 2006; Mould
and Upton, 2013; Shargel, Andrew, and Wu-Pong, 2015). PK modeling uses drug
concentration data sampled at known times from one or more individuals with
known dosage regimens. Population PK modeling uses data from multiple indi-
viduals and distinguishes between population and individual level characteristics
of drug behavior in the body (Mould and Upton, 2013). Often, a mixed-effects
model is used to characterize a population model wherein fixed effects represent
structural population level typical values and random effects variability between
individuals and between occasions. A second level of random effects is typically
included as well to reflect residual variability, or error in model predictions (Bonate
and Steimer, 2006).
Typically, non-linear mixed effects models are used for pharmacological model-
ing of drug concentrations in the body. The NON-linear Mixed-Effects Modeling
(NONMEM) software is frequently used to estimate parameters from a mixed-
effects model (Beal et al., 2009). Parameters of interest include the following:
absorption rate constant, volumes in the central and peripheral compartments,
bioavailability, the proportion of drug administered that reaches circulation, and
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clearance, the rate at which a drug is completely removed from some biologic
matrix (Wakefield, Aarons, and Racine-Poon, 1999; Mould and Upton, 2013; Upton
and Mould, 2014). The mean values of the PK parameters (typical values) are
fixed effects. Variations around these means (both within and between individuals)
are described by random effects. Additionally, individual covariates such as age,
sex, and creatinine clearance modify the fixed effects PK parameters. Residual
variability may be characterized by additive and/or proportional error parame-
ters. Endpoints for PK models include area under the concentration versus time
curve (AUC), peak (maximum) concentration, time to peak concentration, half-life,
trough (minimum) concentration, and time above a predefined threshold. Both
likelihood and Bayesian approaches may be used to estimate the parameters of a
PK model (Mallet, 1986; Racine-Poon and Wakefield, 1998; Wakefield, Aarons, and
Racine-Poon, 1999).
3.1.1 Pharmacodynamic Modeling
In contrast to PK modeling, pharmacodynamic (PD) modeling examines the effects
of the drug on the body, in terms of both drug safety and effectiveness. Often,
the two are distinguished by the following: “what the body does to the drug”
(pharmacokinetic) versus “what the drug does to the body” (pharmacodynamic).
Typically, one or more of the endpoints of the PK model is used as a measure of
exposure in the PD model and related to some outcome of interest in the body. The
analysis conducted in Chapter 2 using longitudinal TMLE is one such example of
a PD analysis.
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3.1.2 Pharmacokinetic Studies of PrEP
A number of PK studies have been conducted to better understand the relationship
between different PrEP dosage strategies and drug concentrations in the body in a
range of populations. PK models developed from these studies quantify levels of
TDF and FTC and their active metabolites, tenofovir diphosphate (TFV-DP) and
emtricitabine triphosphate (FTC-TP) in different compartments, including blood
plasma, peripheral blood mononuclear cells, and tissue.
PK models have been developed from small studies with directly observed
dosing, including the HIV Prevention Trials Network (HPTN) 066 Study of TDF
and FTC in healthy men and women. Hendrix et al. (2016) established steady-
state concentrations of TFV and FTC in the plasma and TFV-DP and FTC-TP in
PBMCs under different oral dosing regimens. Patterson et al. (2011) developed a
PK model in healthy men and women collecting concentration measurements over
the course of two weeks after one oral dose of tenofovir in various compartments
including blood plasma, genital secretions, and mucosal tissues. Importantly, they
characterized the decay of TFV, which is highly relevant for alternative dosing
strategies than daily dosing. They also determined that concentrations of both
TFV and TFV-DP were 100 times higher in colorectal tissues compared to the
female genital tract (Patterson et al., 2011). This finding indicates that target drug
concentrations and dosing strategies may differ between populations at risk of
HIV and by sites of exposure. Louissaint et al. (2013) developed a PK model using
concentration measurements over time in plasma, tissues, blood CD4 cells, and
PBMCs after a single dose of oral PrEP. This work has further contributed to the
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understanding of the rise, accumulation, and decay of tenofovir levels throughout
the body.
Other PK models have been developed using data from clinical trials without
directly observed dosing. For example, (Burns, Hendrix, and Chaturvedula, 2015)
developed a population PK model of tenofovir using data from the MTN-001 open
label clinical trial. In this trial, healthy women were randomized to either or both
of oral tenofovir or tenofovir vaginal gel. An important contribution of the PK
model developed from the MTN-001 trial was that it accounted for varying levels
of study participant adherence. A PK model developed from the Cell-PrEP study
established steady-state concentrations of PrEP in rectal mononuclear cells, an
important site for men who have sex with men (Seifert et al., 2014).
3.2 Methods
We integrate the PK model developed by Vucicevic, Savic, and Hendrix (In Prepa-
ration, 2018) into the longitudinal TMLE framework in Chapter 2. Instead of using
raw plasma concentrations as the drug exposures, we use the average daily steady-
state concentrations at each participant’s study visit generated from the PK model.
The raw concentrations used in the analysis in Chapter 2 are taken at one point in
time and may not represent the level of drug in a study participant’s body over a
period of time. In contrast, the PK model accounts for the time between when a
concentration measurement was taken and when the study participant reported
taking their most recent dose.
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3.2.1 The Pharmacokinetic Model
The pharmacokinetic model that we use is a two-compartment nonlinear mixed-
effects combined additive and proportional residual error model developed by
Vucicevic, Savic, and Hendrix (In Preparation, 2018). The model integrates PK data
from the oral TDF and FTC/TDF arms of three PrEP clinical trials. It has been
built using the largest known clinical trial database of oral tenofovir measurements.
Data from the Partners PrEP and VOICE studies, both of which are described
in Chapter 2, were used to build the model. Additionally, the model integrated
pharmacokinetic data from the Pre-exposure Prophylaxis Initiative (iPrEx) trial, a
multinational, randomized, placebo controlled trial of daily TDF/FTC in 2499 men
and transgender women who have sex with men; (Grant et al., 2010; Anderson et al.,
2012). As with the Partners PrEP and VOICE studies, plasma drug concentrations in
the iPrEx trial were measured from stored samples for a subset of study participants
in the active treatment arms. A nested case-control substudy design was used for
concentration sampling. In all three of the PrEP studies, the oral dose in the active
treatment arms (whether TDF or FTC/TDF) included 300 mg of tenofovir, given
every 24 hours.
The PK model includes two main compartments: the blood plasma (a central
compartment) and a peripheral compartment. They are related by a distribution
parameter Q, the intercompartmental clearance between the central and peripheral
compartments. Absorption of the drug from the oral dosage into the plasma is
characterized by the parameter kA, and clearance of the drug from the plasma by
CL. Figure 3.1 illustrates the structure of the model and the parameters that relate
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the movement of drug into and between the different compartments.
Let A1, A2, andA3 denote the amount of drug in the dosage, oral compartment,
and peripheral compartment, respectively. Additionally, let V2 and V3 denote the
volumes in the central and peripheral compartments and C2 and C3 their respective


























Let C2 = A2V2 and C3 =
A3
V3
denote the concentrations in the central and peripheral
compartments, respectively. When a uniform dose D is given every τ hours, the
concentrations in the central and peripheral compartments as a function of hours
since the last dose, t, are given by the following two equations, whose general form































































(Q/V2 + CL/V2 + Q/V3) +
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(Q/V2 + CL/V2 + Q/V3)−
√
(Q/V2 + CL/V3 + Q/V3)2 − 4Q/V3CL/V2
]
.
The parameters (kA, V2, TVCL, V3, Q) are fixed effects estimated by NONMEM.
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Additionally, NONMEM estimates the random effect η1, which describes individ-
ual level clearance: CL = TVCLeη1 . The population level concentrations in the two
compartments (as functions of time) can be estimated by setting the random effect
η1 to its mean value, 0. An individual concentration curve is generated by using
the person-specific random effect estimated.
Finally, residual error is characterized by two population-level parameters: an
additive and proportional error constant, Wa and Wp, respectively. Let YPK be an
individual predicted concentration based on the PK model and YTRUE the true
concentration. The additive and proportional residual variability structure defines:
YTRUE = YPK + Wa + YPK × Wp.
The PK model incorporates varying levels of participant adherence and re-
sulting concentration measurements below the limit of quantification. Although
plasma concentration samples were used from participants with a reported dosing
within 100 hours, 43% of all plasma measurements across the studies were below
the limit of quantification (which was 0.31 ng/mL in Partners PrEP and VOICE
and 10 ng/mL in iPrEx), and 50% of participants had at least one observation
below the limit of quantification. To account for below quantifiable concentration
measurements, Vucicevic, Savic, and Hendrix (In Preparation, 2018) maximized
the likelihood for observations above the limit of quantification and treated obser-
vations below the limit of quantification as censored (Ahn et al., 2008; Bergstrand
and Karlsson, 2009).
Participant non-adherence was accounted for by estimating the probability
that a study participant took their assigned drug at a particular study visit. This
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subject-visit specific parameter is denoted by padher. A fully adherent individual
would have padher = 1, and decreasing values of padher reflect lower levels of
adherence. A mixture model that identifies adherent (padher = 1) and non-adherent
(padher = 0) subpopulations was used.
An empirical Bayes approach was used to estimate the subject-specific phar-
macokinetic parameters in NONMEM with a First Order Conditional Estimation
(FOCE) method (Beal et al., 2009). The standard errors of the empirical Bayes
estimates of the random effects were estimated using the method of Kang et al.
(2012). Average daily tenofovir concentrations at steady-state for a particular study
participant at each of their visits were estimated using the fixed effects estimates,
their random effect estimates, and their individual probabilities of taking the drug
at each study visit.
The exposure we will use in our PD analysis is the average steady-state con-
centration at each participant-visit. Steady-state is the period in which the rates of
drug intake into and elimination from a given compartment are equal. The average




3.2.2 Longitudinal Targeted Maximum Likelihood Estimation
We repeat the longitudinal TMLE analysis from Chapter 2 using the average daily
tenofovir concentrations at each participant-visit from the PK model in place of the
raw concentrations. We use a threshold of 40 ng/mL to define a high concentration
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regimen. The PK model was developed using only the oral TDF and oral FTC/TDF
arms of PrEP trials, so we omit the gel arm of VOICE in our analyses.
3.3 Results
3.3.1 Pharmacokinetic Model Results
The parameters of the pharmacokinetic model from this data were similar to those
determined from smaller, more intensive PK sampling studies for PrEP. Notably the
subject-visit specific probability of adherence, padher, have a bimodal distribution
for all of the studies.
We compare the distributions of the raw and modeled average tenofovir concen-
trations for both the Partners PrEP and VOICE studies in Figure 3.2. PK visits that
occurred more than 100 hours after the last reported oral drug dose are excluded
from the raw drug concentration data so that the raw and modeled tenofovir con-
centrations are from the same set of participant visits. Both the raw and modeled
concentrations have multimodal distributions, differentiating study participants
into several adherence subpopulations. There are a substantial number of raw con-
centrations below the limit of quantification (0.31 ng/mL), particularly among the
VOICE oral study arms. In contrast, all of the average daily steady-state tenofovir
concentrations generated by the PK model are above the limit of quantification.
This likely reflects the considerable shrinkage of the parameter padher (by 43%), so
that all subject-visit probabilities of adherence are nonzero. As a result, average
steady-state concentrations for non-adherent participants may be inflated.
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In Figure 3.3 we compare the raw and steady-state average daily concentrations
from the PK model by participant visit. Both the raw and modeled concentration
measurements are clustered into different subpopulations of adherers, occasional
adherers, and non-adherers. However, their values are not directly comparable
because the raw concentration measurements are from a point in time (typically
shortly before the next dose is taken) and approximate trough concentrations,
while the modeled values are average steady-state concentrations over the course
of a day. The modeled concentrations also include considerable shrinkage towards
typical (high) levels of adherence.
3.3.2 LTMLE Analysis Results
We present the results of the LTMLE analysis looking at the estimated risk of
setting average daily steady-state concentration to above or below 40 ng/mL at
each of the first three semi-annual visits in Table 3.1. The estimated HIV incidences
and relative risk reductions are very similar in each of the studies comparing the
analyses adjusting only for baseline variables to those adjusting for both baseline
variables and time-varying risk behaviors. In both studies, setting participants
to follow a concentration regimen of above 40 ng/mL at each of the 6, 12, and 18
month study visits suggests a protective effect against HIV infection. However, the
confidence intervals in the Parters PrEP analysis when adjusting for time-varying
risk and in both of the VOICE analyses are very wide and overlap zero.
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3.3.3 Comparison of Results Using Raw vs. Modeled Concentra-
tions
The results of the longitudinal TMLE analyses are similar whether using the raw
or modeled concentrations. In the Partners PrEP study, when adjusting for time-
varying risk behaviors, the estimated relative risk reduction setting average daily
steady-state concentration (based on the PK model output) to above 40 ng/mL
at each of the 6, 12, and 18 month visits is 91% (95% CI: −13, 98). Similarly,
the estimated relative risk reductions (based on the raw concentration) setting
concentration to above 0.31 ng/mL and to above 40 ng/mL are 82% (95% CI: 8, 94)
and 84% (95% CI: 10, 95), respectively. The estimated relative risk reductions are
also similar when adjusting only for baseline variables, although the confidence
intervals are narrower.
In the VOICE study, using the modeled concentrations we estimate a 62%
(95% CI: -9, 90) when setting average daily steady-state concentration to above 40
ng/mL and adjusting for both baseline variables and time-varying risk. As with the
analyses of the raw concentration data, we estimate the effect of longitudinal PrEP
drug concentration to be in the direction of benefit, but the confidence interval for
the estimated effectiveness overlaps zero. As discussed in Chapter 2, our estimate
of the risk of seroconversion setting (raw) concentration to above 40 ng/mL at
each of the 6, 12, and 18 month visits in the VOICE oral arm was unstable, so we
can only compare setting observed concentration to above versus below the limit
of quantification (0.31 ng/mL) to setting the modeled average concentrations to
above versus below 40 ng/mL.
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As previously discussed, study visits where the time from last reported dose
taken to time of specimen collected exceeded 100 hours, as well as those where the
time was unknown, were excluded from the PK model. As a result, more study
participants were artificially censored when performing the LTMLE analysis on
the PK output as compared to the raw plasma concentrations. The rationale for
excluding participants after 100 hours was that based on its half life, by 100 hours
after the most recent dose, all of the tenofovir has been completely eliminated
from the body. Therefore, there may have been fewer observations where a study
participant had no drug when they were at risk of seroconversion in this analysis
as compared to the analysis using raw tenofovir concentrations. We repeated the
longitudinal TMLE analysis using the raw concentration data restricted to PK
measurements taken within 100 hours of the last reported dose. Our estimates of
HIV incidences and effectiveness were almost identical to those from the analyses
using all of the raw concentration measurements.
3.4 Discussion
We utilize the methodology of Chapter 2 in combination with pharmacokinetic
models developed from the oral TDF and FTC/TDF arms of the Partners PrEP
and VOICE studies, with additional pharmacokinetic data from a third clinical
trial. Using modeled rather than raw concentrations reduces the influence of
the time of recent dose, especially if within the last day or two, on measured
concentration. This is important because plasma tenofovir has a short enough
half-life that concentration levels will vary substantially over the course of a one
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day dosing window. The population PK model borrows information between
individuals both within the same study and across studies while still accounting for
variability among study participants and among visits for an individual participant.
This is particularly beneficial given the sparsity of concentration measurements.
Although not directly comparable, the results of the longitudinal TMLE analysis
using average daily concentrations generated by the PK model are consistent with
the results using raw concentrations. The raw concentrations are systematically
lower than the steady-state concentrations from the PK model, so there were too
few raw concentration measurements in the VOICE oral arm exceeding 40 ng/mL
to estimate this effect.
An important limitation is that we do not know when study participants are
exposed to HIV. The PK model has the strength of accounting for the length of time
between when the last dose and the plasma sample were taken, thus allowing us to
capture a study participant’s average concentration over a period of time. However,
the true exposures of interest, a study participant’s drug concentration(s) at their
time(s) of HIV exposure are unattainable. Additionally, this analysis requires
the same set of assumptions as in Chapter 2. Further, the average daily steady-
state concentrations generated from the PK model require the strong assumption
that average daily steady-state concentration is proportional to the probability of
adherence at a study visit.
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3.4.1 Future Directions
Further development of the pharmacokinetic model will largely guide areas of po-
tential future research. Thus far, the PK model has focused on drug concentrations
from oral tenofovir dosing. An expansion of the model to include gel dosing will
allow us to extend our analyses in Chapter 2 of the VOICE gel arm. As discussed in
Hendrix (2013), tenofovir concentrations in multiple sites of the body are relevant
for protecting against HIV infection. The most important compartments differ by
at-risk population due to both biological differences and varying sites of infection
(Hendrix, 2013). Understanding their relative contributions to HIV protection
remains an ongoing challenge. An extension of the PK model to quantify the
movement of drug in additional compartments, such as tissues and peripheral
blood mononuclear cells, may allow us to estimate the protective effect of drug
concentrations in different compartments of the body that may be more relevant
than blood plasma. This may be particularly useful for comparing different routes
of dosing, such as oral versus vaginal gel tenofovir. Mediation analyses may be a
useful tool for discerning the protective effects of concentration levels in different
compartments against HIV risk.
Another important development may be modeling additional patient level
covariates. In the PK model so far, adherence has been categorized using pharma-
cological measures (drug concentrations). As a result, it is not possible to model
concentrations for a study participant not included in a concentration substudy (as
the PK measures needed to characterize their levels of adherence are unmeasured).
Incorporating additional study participant level characteristics may allow for the
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prediction of drug concentration levels in study participants in the treatment arms
who were not included in the concentration substudies.
Finally, we are exploring the possibility of developing a Bayesian hierarchical
model as a method to integrate the output from the PK model into an analysis of
the effect of tenofovir drug concentration on risk of HIV infection. This framework
has the potential advantage of better utilizing the characterizations of variability
output from the PK model in the form of parameter distributions for both the fixed
and random effects. In particular, the PK model can be used to generate for each
study participant a collection of possible concentration-time curves and associated
average daily tenofovir concentrations from the individual level parameter dis-
tribution. These generated concentrations can represent the bottom level in the
hierarchical population PK model.
An ongoing challenge with the Bayesian model is accounting for the case-cohort
and nested case-control sampling schema from the trials. In the LTMLE analyses,
both with the observed and modeled concentrations, we used weighting. We do
not know of a natural extension of the inverse weighting approach in the Bayesian
analysis. One promising method, which has been used in other PrEP analyses,
including a PK/PD analysis by Anderson et al. (2012) is multiple imputation for
all study participants not included in the concentration substudies. However, as
discussed in Chapter 2, adherence as reported by study participants and measured
from returned pills often is only weakly correlated with adherence levels estimated
from plasma samples, especially in the VOICE study (Van der Straten et al., 2014;
Marrazzo et al., 2015; Dai et al., 2015). We also found that estimated levels of
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adherence from the the population PK model differed substantially from self
reported levels of adherence and adherence calculated using pill counts. As a result,
the reliability of any predictions of concentration levels for study participants
lacking any pharmacological measurements seems limited. Incorporating the
sampling schema in a Bayesian framework may be an alternative approach to
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Figure 3.1: The two compartment population-level PK model used to model tenfovir
plasma concentrations from oral dosing.KA, Q/V2 and Q/V3 are first order rate constants
that characterize the movement of tenofovir from the oral dosage to the plasma (com-
partment 2) to the peripheral compartment (compartment 3). This figure is adapted from
Scheme 4 of Fundamentals of Clinical Pharmacokinetics (p. 198) by J. G. Wagner, 1975, Drug
Intelligence Publications, which illustrates the basic structure of the two-compartment
model we used.
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 Modeled vs. Raw Concentrations
(b)
Figure 3.2: Comparison of the distribution of raw plasma tenofovir concentrations from
stored samples and estimated daily concentrations from the pharmacokinetic model in
the Partners PrEP (top) and VOICE (bottom) oral arms. The two vertical lines show the
values of 0.31 ng/mL, the limit of quantification of tenofovir for both studies, and 40 ng/mL,
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Figure 3.3: Comparison of average daily tenofovir levels from the pharmacokinetic
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4.1 Introduction
4.1.1 Cluster randomized trials for health services research
Community engagement interventions may improve health outcomes in pop-
ulations with complex needs, and their implementation and evaluation are of
interest for health services research. Evaluation of such multi-component inter-
ventions can be challenging, and published evaluations are often threatened by
confounding factors. For example, a large body of literature exists on the promo-
tion of breast-feeding to reduce diarrhoeal diseases in infants, such as Béhar (1975),
Victora et al. (1987), Dewey, Heinig, and Nommsen-Rivers (1995), Arifeen et al.
(2001), and Lamberti et al. (2011). However, sources of confounding including
infant age and mothers’ socioeconomic status, education level, reliance on child
care, self-perception, and maternal attitude raise methodological challenges (Sauls,
1979; Feachem and Koblinsky, 1984). Similarly, community-based interventions to
control the spread of dengue face a range of confounders, including climate and
adherence (Heintze, Garrido, and Kroeger, 2007).
Cluster randomized trial designs are useful for evaluating the effectiveness of
community-based interventions to reduce issues of confounding and bias (Hayes
and Moulton, 2017). Such trials randomize social units, such as classrooms, schools,
athletic teams, villages, hospitals, or workplaces (Donner and Klar, 2000). As we
will discuss in more detail, the design and analysis of cluster randomized trials
require special considerations because, although clusters are randomized to study
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arms, individual-level outcomes within a cluster are often of interest to investi-
gators (Donner and Klar, 2000; Hayes and Bennett, 1999). Correlations between
individuals within a cluster must be accounted for in both sample size calculations
and the analysis of outcomes (Donner, Birkett, and Buck, 1981; Raudenbush, 1997;
Hayes and Bennett, 1999).
Many of the advantages of cluster randomized trials (CRTs), are relevant to
health services research and community based interventions. In some cases, fea-
sibility calls for designing and implementing randomization on a cluster level
(Donner, 1998). Examples include the influential study by Sommer et al. (1986)
on the effect of Vitamin A supplementation in Indonesia on reducing childhood
mortality and in the mass education intervention in the Community Intervention
Trial for Smoking Cessation (Fisher Jr, 1995). In others, the outcome of interest may
be on the cluster level, such as when studying herd immunity through vaccination
(Smith, Morrow, and Ross, 2015). Cluster randomization may also be appropriate
when the primary goal is to demonstrate efficacy at a group or community level
(Smith, Morrow, and Ross, 2015). Additionally, ethical considerations may motivate
cluster randomization (Fairhurst and Dowrick, 1996; Hussey and Hughes, 2007),
although additional challenges, such as informed consent, may arise from cluster
randomization (Taljaard et al., 2011; Sim and Dawson, 2012; Weijer et al., 2012).
Finally, cluster randomization may be utilized for practical considerations, such
as accounting for individual-level contamination and peer-motivated compliance
(Hussey and Hughes, 2007).
CRTs present unique statistical challenges. Factors such as subject selection,
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influential cluster-level covariates, and the spread of infectious diseases among
people in regular contact with one another cause correlations among individuals
within a cluster (Donner and Klar, 2000). Identifying clusters by geographic loca-
tion can result in spatial correlation (Taljaard et al., 2011). These correlations almost
always inflate the variance of effect estimates and reduce power and efficiency
relative to a trial that randomizes the same number of independent individuals
(Donner, Birkett, and Buck, 1981; Donner, 1998; Hayes and Bennett, 1999; Klar
and Donner, 2001; Donner and Klar, 2004). Additionally, for a fixed number of
individuals, the number of randomized units will be much smaller in a CRT, so the
likelihood of chance imbalance on features increases (Moulton, 2004).
The concern about imbalances between treatment groups may be partially ad-
dressed by imposing constraints on the randomization schema. Constrained (also
referred to as restricted) randomization may be implemented in a CRT, whereby a
set of balance criteria on certain covariates are determined prior to the randomiza-
tion (Moulton, 2004). As detailed in Hayes and Moulton (2017), such criteria may
include upper bounds on the difference in means (or proportions) across treatment
arms for numerical (or categorical) variables.
In conjunction with constrained randomization, statistical adjustment for chance
imbalances in other baseline covariates between treatment groups may be used
to improve precision and power in the analysis of CRTs (Gail et al., 1996; Braun
and Feng, 2001; Small, Ten Have, and Rosenbaum, 2008). A statistical method for
leveraging baseline variables in the analysis, as developed by Small, Ten Have, and
Rosenbaum (2008), is described in Section 4.2.2.
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Standard analyses of cluster randomized trials are based upon a statistical
model to describe the data generating process. Analyses may be performed in one
stage as an individual-level analysis, or in two stages as a cluster-level analysis;
however, both have several drawbacks. Although Hayes and Moulton (2017)
recommend using a cluster-based analysis when the treatment groups contain
15-20 or fewer cluster each, both approaches may lack robustness to the model
assumptions when there are very few clusters in each treatment arm.
Additionally, model-based analyses may not be suitable when spillover (inter-
ference) occurs between clusters. Spillover, wherein the treatment received by one
unit affects the outcomes of another unit, may attenuate or inflate the true effect of
a treatment, depending upon its mechanism (Sobel, 2006; Tchetgen and Vander-
Weele, 2012; Aronow and Samii, 2013; VanderWeele, Tchetgen, and Halloran, 2014).
Often, analyses of cluster randomized trials, while accounting for spillover within
a cluster, assume no spillover between different clusters. Model-based analyses
that do account for spillover between clusters must make additional assumptions
about the mechanism of spillover.
Randomization inference offers an alternative to model-based analyses. It
uses only the randomization process itself for making inferences by comparing
the value of the observed test statistic to its collection of possible values from all
permutations of the treatment assignment labels (Fisher, 1935; Rosenbaum, 2002).
Randomization inference tests the null hypothesis of no primary treatment effect,
meaning “the treatment confers no more benefit or harm to treated units then it
confers to untreated controls” (Rosenbaum, 2007). In particular, the null hypothesis
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includes the both the scenarios where the treatment has no effect on any cluster and
where the treatment affects all clusters equally. Randomization inference has the
added benefit of addressing the challenge of spillover effects. The data-generating
process of the outcomes does not affect the distribution of the test statistic under
the null hypothesis of no primary treatment effect, even if it includes interference
between units (Rosenbaum, 2007).
Although CRTs may be strengthened by the use of constrained randomization,
randomization inference, and adjustment for prognostic baseline variables (at
both the individual and cluster level) (Li et al., 2015), this combination of all three
tools has, to the best of our knowledge, not yet been applied to a community-
based intervention. In this chapter, we present the design and analysis of a CRT
developed to strengthen connections between community based organizations in
East Baltimore and improve the health of the clients they serve. We aim to address
the following question: what are the strengths and weaknesses of using a balanced,
covariate-adjusted, cluster randomized trial design for evaluating effectiveness
of a community engagement intervention for strengthening connections among
hospitals and clinics, community based organizations, and community?
4.1.2 Baltimore CONNECT Project
The Baltimore Community Organizations Neighborhood Network: Enhancing Ca-
pacity Together (CONNECT) Project was a community engagement and research
partnership between the Johns Hopkins Health Systems (JHHS), community-based
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organizations (CBOs) in East Baltimore, and residents of East Baltimore neighbor-
hoods. The study, funded by the Patient Centered Outcomes Research Institute
(PCORI), aimed to improve the health of East Baltimore residents by leveraging al-
ready available resources and social structures, and fostering a sustainable network
of community and health care organizations. A community engagement approach
was used to co-develop and apply a capacity building intervention among a group
of CBO partners and the Baltimore CONNECT study team (Wu et al., 2018).
A systematic process was used for identifying all candidate community based
organizations. First, the IRS Master file of Tax Exempt Organizations was consulted;
second, all non-profit organizations that resided in or near the following J-CHiP
(Berkowitz et al., 2016) zip codes: 21202, 21205, 21213, 21219, 21222, 21224, 21231
were identified; third, the National Taxonomy of Exempt Entities Classification
System was used to further include only organizations that provided health and
human services, and those that engaged in the direct delivery of services to adults.
The organizations include were limited to those with 501(c) 3 status, and excluded
social services run by city, state or federal government agencies. After creating a
tentative list of CBOs that fit the minimum inclusion and exclusion criteria, a list of
these organizations, along with their contact information, a description of the type
of services provided, and mission statements was presented to the stakeholders at
our first stakeholder meeting for further input. After refining the list, all eligible
community organizations were invited to an information session to explain the
details of the study. Those who expressed interest in the study were invited to
participate; of those invited, twenty-two organizations accepted the invitation for
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enrollment into the study.
The methods for constrained randomization to assign CBOs to the intervention
or control study arms are delineated in Section 4.2. We refer to CBOs assigned to
the intervention and control study arms as iCBOs and cCBOs, respectively. One of
the iCBOs dropped out of the study prior to baseline data collection, and one of
the cCBOs closed before follow-up. Our analyses were based on the twenty CBOs
that remained in the study.
A community engagement intervention was developed and implemented
among the intervention CBOs. Components of the intervention, detailed by Wu
et al. (2018), included the following: monthly meetings among the intervention
CBOs, an online toolkit of resources, a subscription to the search engine Healthify,
a research assistant, and meet-and-greet sessions between staff members from
the intervention CBOs and the Johns Hopkins Health System. The goal of the
intervention was to improve the health of East Baltimore residents.
The effectiveness of the intervention was evaluated using administrative claims
data made available through the John Hopkins Community Health Partnership
(J-CHiP) (Berkowitz et al., 2016). Funded by the Center for Medicare and Medicaid
Innovation, J-CHiP was a large initiative conducted at Johns Hopkins Hospital and
Johns Hopkins Bayview Medical Center to improve the coordination and quality
of care in Johns Hopkins Health Care inpatient and outpatient settings (Berkowitz
et al., 2016). The J-CHiP population consisted of all Priority Partners (Medicaid)
Managed Care Organization and Medicare patients who: 1) were identified for
the J-CHiP program by either a risk prediction model or referral; 2) passed a
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screening process; and 3) had monthly utilization data available, including number
of emergency department (ED) visits and days spent in the hospital. Records were
analyzed for 4917 patients.
Because of CBO client confidentiality, we were unable to determine which, if
any, of the twenty CBOs in the study each J-CHiP patient utilized. We assumed
that individuals seeking services from CBOs are more likely to utilize the services
of CBOs that are geographically closer to where they live compared with CBOs
that are farther away. We used Google API to determine the distance between the
home address of each patient enrolled in J-CHiP and each CBO and determined
the closest CBO to each patient; this is called the “proximal CBO” for each patient.
The primary analysis used a difference-of-differences approach. We compared
the changes in the number of emergency department (ED) visits and days spent in
the hospital from before and after the capacity building intervention; this control
was done between J-CHiP patients proximal to the iCBOs and J-CHiP patients
proximal to the cCBOs. Though it would have been preferable to directly measure
the impact of the intervention on CBO clients, it was not feasible to do this.
Spillover was a major concern in the analysis of this study. If a CBO’s set
of clients includes a J-CHiP patient geographically closer to another CBO, the
treatment assignment of the former CBO may affect outcomes measured at the
latter CBO. CBO staff and client surveys indicated a network of communication
and referrals between the different organizations, which the intervention sought
to foster (Wu et al., 2018). As a result, spillover was very plausible. We used





As previously discussed, cluster randomized trials risk imbalance on important
variables, motivating the use of constrained randomization (Moulton, 2004). We
summarize the steps of a constrained cluster randomization schema based on
variables of interest (Moulton, 2004), and we provide examples of each step from
the Baltimore CONNECT project.
1. Determine cluster-level characteristics that may be prognostic of the outcome
of interest. These may be characteristics of the clusters themselves or cluster-
specific summary measures of individual characteristics (Raab and Butcher,
2001). We applied the following randomization criteria. For any zip-code
serviced by more than one CBO, at least one CBO in that zip-code must be
randomized to each of the control and intervention arms. For any service
type provided by more than one CBO in the study, at least one CBO of that
type must be randomized to each of the control and intervention arms.
2. Enumerate all the possible allocations of treatment and control to the clusters.
Supposing there are K clusters included in the randomization, with KT as-
signed to the treatment and KC = K − KT assigned to the control, there will
be ( KKT) total allocations. In the Baltimore CONNECT study, we randomized
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11 of the 22 CBOs to the intervention arm and the other 11 to the control arm,
for a total of 705,432 possible treatment assignments.
3. Select the allocations that fit the criteria determined in (1). Out of the 705,432
possible treatment allocations, 2636 obeyed both the zip code and service
type constraints.
4. Construct a square matrix with columns and rows enumerated by the clusters,
where each entry gives the number of times the associated pair is assigned
the same study arm (treatment or control) from the list of allocations in (3).
5. Examine the matrix for pairs of clusters that are (nearly) always or (nearly)
never in the same study arm; these are indicators of over-restriction in the
randomization constraints. If the allocation list does not have these problems,
continue to (6). If the list is unacceptable, relax (or tighten) criteria and return
to (3). Our validity matrix had six zeroes (pairs of CBOs always assigned to
different study arms) and one pair of CBOs always assigned to the same arm,
which we considered acceptable.
6. Among the list of allocations in (3) deemed acceptable, randomly select one
to proceed with.
An important decision in implementing constrained randomization is how
many constraints to include. More constraints can lead to better balance, but
can impact both the power of the trial and the validity of the randomization.
Validity refers to the lack of linkage among clusters in the randomization scheme,
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so that the more uniform the distribution of the elements of the matrix in step (4),
the greater the validity (Bailey and Rowley, 1987). An invalid design can cause
statistical inference to have incorrect Type I error and confidence interval coverage
(Moulton, 2004). One can avoid an overly constrained randomization by checking,
among the acceptable treatment assignments, for pairs of clusters that are always
or never assigned to the same treatment arm. If such pairs are identified or the
number of acceptable treatment assignments is very small relative to the number
of possible unconstrained treatment assignments, it may be beneficial to relax the
randomization criteria (Moulton, 2004; Hayes and Moulton, 2017).
4.2.2 Randomization Inference
We used randomization inference to test the null hypothesis of no effect of the
intervention on any individuals in the study population. We compared the esti-
mated treatment effect under the actual randomization compared to all the other
ways the randomization could have occurred (Murray, 1998; Small, Ten Have, and
Rosenbaum, 2008). In our constrained randomization, there were 2636 allowable
treatment allocations, each of which had a 12636 probability of being implemented.
We recalculated the difference-in-differences test statistic for each of the 2635 other
possible allocations of the treatment assignments that met the randomization cri-
teria. The p-value is defined as the proportion of treatment assignments yielding
a difference-in-differences statistic of magnitude greater or equal to the observed
statistic.
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The primary outcome for J-CHiP patients was the difference between the av-
erage monthly sum of ED visits and days spent in the hospital in the period after
as compared to before the intervention. The test statistic was the difference-in-
differences in the average number of monthly ED visits and hospital days from
the post intervention period as compared to the pre-intervention period between
iCBOs and cCBOs. We adjusted for the following baseline individual-level vari-
ables that may be prognostic of outcomes: baseline utilization, age, gender, and
insurance type.
We present methods for a covariate adjusted, permutation-based, randomiza-
tion inference analysis developed by Rosenbaum (2002) and Small, Ten Have,





nk individuals. Let Zk be an indicator that cluster k is assigned to the
intervention study arm. The algorithm for the analysis is as follows.
1. For each eligible patient, average the monthly sum of ED visits and days
spent in the hospital in the pre-intervention period, from 9/1/12 to 2/28/14.
For individual i in cluster k, call this value R1ki.
2. For each eligible patient, average the monthly sum of ED visits and days
spent in the hospital in the post-intervention period, from 4/1/14 to 9/30/15,
and denote this value R2ki.
3. Calculate for each patient a change score over the course of the study, from the
average monthly sum of ED visits and hospital days in the pre-intervention
period to the post-intervention period. The change score for individual i in
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cluster k is Rki := R2ki − R1ki.
4. Regress the change score outcomes from all study participants on a set of
individual characteristics observed prior to randomization X (baseline uti-
lization, age, gender, and insurance type), using a linear model. Calculate the
residuals from the regression, and for individual i in cluster k, denote their
adjusted response (residual) e0ki.









6. Determine the difference between the weighted average of the adjusted
change scores among the intervention CBOs and the control CBOs. For both
the control and intervention groups, weights should be proportional to to the
number of J-CHiP patients assigned to each CBO, nk. The weighted averages




















The difference-in-differences statistic, Ŝ, is defined as:
Ŝ := eT − eC
7. Recompute the test statistic in (6) under all of the 2635 other possible alloca-
tions of the treatment assignments. Call these statistics Ŝ∗.
8. Compare the distribution of the permuted Ŝ∗ in (7) to the observed Ŝ in (6)
from the true treatment assignments. The proportion of the Ŝ∗ with values as
or more extreme (higher in magnitude) than that of Ŝ is the p-value. The null
hypothesis of no treatment effect is rejected at level α = 0.05 if the p-value is
less than α.
For the unadjusted analysis, omit Step 4 and proceed in the remaining steps using
the Rki in place of the e0ki. In Section 4.7, we describe how to construct confidence
intervals using randomization inference. Unlike the hypothesis testing, the confi-
dence interval construction requires the assumptions of constant treatment effect
and no spillover.
4.2.3 Notation and Justification for Randomization Inference
Randomization inference employs a potential outcomes framework (Rosenbaum,
2002; Small, Ten Have, and Rosenbaum, 2008). The following justification for using
randomization inference in the presence of potential spillover of the treatment
impact uses key ideas from Rosenbaum (2007). We define a potential outcome
(change in ED visits plus days in the hospital) rkiπ for each individual i with
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proximal cluster k under each treatment assignment π to all clusters (i.e., π is one
of the 2636 allowed treatment permutations to all clusters). The observed outcome
Rki is the potential outcome rkiΠ where Π is the selected treatment assignment (to
all clusters).
The null hypothesis of no treatment effect is that rkiπ1 = rkiπ2 for any assign-
ments (permutations) π1, π2. That is, the null hypothesis is that there is no impact
on any individual of assigning any set of clusters to the intervention versus the
control. This null hypothesis implies no effect on a participant of assigning her/his
cluster to treatment versus control; it also implies more: that there is no impact
from assigning any set of clusters (among those allowed by the constrained ran-
domization) to the intervention versus control.
We based our inference upon the difference-in-differences statistic, which is
a function of the observed responses. Under the null hypothesis of no treatment
effect, the test statistic constructed from any possible permutation of the study
assignments will be equally likely because every individual will have the same
potential outcome regardless of their cluster’s assignment to treatment or interven-
tion.
We adjusted for baseline variables to try to remove variability in the outcome
explained by the baseline variables as follows. Denote by R the N-dimensional
vector of the observed individual responses and by X an N × p matrix of p baseline
variables measured on each individual before the intervention. Calculate the
difference (i.e., the residual, denoted by e0ki) between the observed outcomes R
and the projection of the outcomes R onto the space spanned by the covariates X.
94
This residual is a function of the observed data (the outcomes R and covariates
X), and its calculation makes no assumptions about the data generating process
itself (Small, Ten Have, and Rosenbaum, 2008). Similarly, the adjusted difference-
in-differences statistic is a function of the observed data, and only the study arm
assignments are random. As a result, we can characterize the distribution of
the adjusted difference-in-differences statistic under the null hypothesis of no
treatment effect without any distributional assumptions about how outcomes were
generated.
4.3 Results
Overall health care utilization stayed constant from the pre- to post- intervention
periods. Both the monthly number of ED visits and days in the hospital had
constant means of 0.19 and 0.39, respectively, and medians of zero.
The results of the difference-in-differences analyses are summarized in Table 4.1.
The unadjusted and adjusted difference-in-differences statistics are very close to
zero, and we cannot reject the null hypothesis that the intervention had no effect on
the before-after change in total ED visits and hospital days for J-CHiP patients in
the study. The width of confidence interval for the difference-in-differences statistic
is reduced by 15% adjusting for baseline variables.
Because the confidence intervals were determined using randomization infer-
ence, as detailed in Section 3.3, their interpretation assumes a constant treatment
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effect. For example, in the second row of Table 4.1, we may conclude 95% confi-
dence that if the treatment effect is constant across individuals, after adjusting for
baseline variable it will be between -0.115 and 0.108.
In contrast, confidence intervals determined through model-based analyses do
not require the assumption of constant treatment effects but instead employ other
strong assumptions. The next section compares our analyses with a model-based
approach.
4.4 Comparison with Model-Based Analysis
4.4.1 Methods
Model-based analyses are typically conducted in one or two stages. In a one-stage
approach, outcomes are modeled on the individual level. Within cluster corre-
lations are typically accounted for by using mixed effects models or generalized
estimating equations (Hayes and Moulton, 2017). Additionally, terms may be
included in the model to adjust for pre-intervention variables (Hayes and Moulton,
2017).
The two-stage approach is as follows. In the first stage, a summary statistic is
obtained for each cluster based on individual-level data; in the second stage, the
summaries are compared, for example with a two-sample t-test. Pre-randomization
individual and/or cluster-level variables can be adjusted for by regressing individ-
ual outcomes on them; the individual-level residuals, rather than outcomes, are
then used to calculate cluster-level summaries (Hayes and Moulton, 2017).
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One-stage analyses are typically more efficient. However, Hayes and Moulton
(2017) recommend performing two-stage analyses when there are 15-20 or fewer
clusters in each study arm because they typically are more robust to model assump-
tions than one-stage analyses are when the number of clusters is small. Because
our study had only 10 cCBOs and iCBOs each, we compared our results from the
previous section to a two-stage, model-based analysis.
In the first stage of the model-based analysis, we determined a summary mea-
sure for each CBO based upon individual-level data, following steps 1-5 of the
analysis detailed in Section 4.2.2 to generate an adjusted change score e0k for each
of the CBOs. In the second stage, we compared the adjusted change scores between
the cCBOs and iCBOs using an unpaired t-test. Following the recommendation
in (Hayes and Moulton, 2017), we did not incorporate cluster-level weights. The
average difference-in-differences for patients assigned to the cCBOs and iCBOs, ēC




































(e0k − ēT)2 + ∑
k:Zk=0
(e0k − ēC)2
K − 2 .
In this model-based analysis, we assumed that the cluster-level outcomes (av-
erage differences in patient utilization from baseline to follow-up) are normally
distributed and that the variance of the cluster-level outcomes is constant. How-
ever, these two assumptions are difficult to assess in a study with only twenty
clusters in total.
4.4.2 Results
The unadjusted and adjusted difference-in-differences statistics from the two-stage,
model-based analysis are given in Table 4.2. The difference-in-differences statistics
(unadjusted and adjusted) varied slightly between the permutation and model-
based analyses because in the latter the clusters are unweighted. However, the
conclusion of no treatment effect remained the same.
4.5 Discussion
We presented an application of a constrained cluster randomized design in health
services research and detailed the process of study design and analysis. This
approach may be of use for future community-based participatory research. We
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illustrated that adjusting for baseline variables in the difference-in-differences
analysis using methods developed by Rosenbaum (2002) can substantially improve
efficiency in a randomization inference analysis. No model assumptions are needed
in the randomization inference approach, meaning the test is valid regardless of
whether the linear regression model used to adjust for baseline variables was
correctly specified or not. A key part of the intervention in the study was the
creation of a network between the CBOs, so we expected spillover effects, and
benefited from the fact that when “randomization forms the basis for inference,”
such as a permutation test of a cluster randomized trial, the level of significance will
be valid regardless of whether there is spillover between units in the intervention
and control arms (Fisher, 1935; Rosenbaum, 2007).
Our analysis of the Baltimore CONNECT study had several limitations. The
confidence intervals we constructed for the difference-in-differences statistics using
randomization inference (see Section 4.7 for details) are valid only if the effect of the
intervention is constant, meaning the difference in change scores if an individual
were assigned to an iCBO as compared to a cCBO is the same among all study
participants. Further, we were only able to test the sharp null hypothesis that the
intervention did not have an effect on any of the units. We could not determine
whether there was a population level average benefit, or, for example, how many
days in the hospital and ED visits could be saved through the intervention on
average (Small, Ten Have, and Rosenbaum, 2008; Rosenbaum, 2007).
Finally, it was observed that the iCBOs did not all participate in the intervention
to the same extent. One possible extension may be adopting methods developed by
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Rosenbaum (1996) for exact randomization inference using instrumental variables,
which has since been employed for a range of applications (Greevy et al., 2004;
Rosenbaum, 2002; Imbens and Rosenbaum, 2005).
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Difference-in-Differences p-value Confidence Interval
Statistic
Unadjusted utilization 0.005 0.926 (-0.130, 0.127)
Adjusted utilization 0.018 0.627 (-0.115, 0.108)
Table 4.1: Results from the difference-in-differences analyses using randomization in-
ference. Utilization is defined as a patient’s monthly number of emergency department
visits and days spent hospitalized. In both the unadjusted and adjusted analyses, we fail to
reject the null hypothesis of no treatment effect.
Difference-in-Differences p-value Confidence Interval
Statistic
Unadjusted utilization 0.002 0.982 (-0.144, 0.141)
Adjusted utilization 0.037 0.652 (-0.205, 0.132)
Table 4.2: Results from the difference-in-differences analyses using a two-stage model.
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4.7 Appendix: Confidence Interval Construction
We present the methods for confidence interval construction under randomization
inference (a continuation of Section 4.2.2). We note that unlike the hypothesis tests,
these confidence intervals incorporate assumptions of both a constant treatment
effect and no spillover.
First, construct a function that adjusts the change score for baseline characteris-
tics by extracting the residuals from a linear regression of the outcomes R on the
individual-level baseline variables X :
g : (Xki, Rki) ↦→ e0ki.
The function g calculates the difference (i.e., the residual, denoted by e0ki) between
the observed outcomes R and the projection of the outcomes R onto the space
spanned by the covariates X. It is a function of the observed data that makes
no assumptions about the data generating process itself (Small, Ten Have, and
Rosenbaum, 2008). After following steps 1 through 8 of Section 4.2.2, the endpoints
for a 95% confidence interval can be calculated using the following method detailed
in Rosenbaum (2002) and Small, Ten Have, and Rosenbaum (2008) and extended to
handle arbitrary interference as in Aronow and Samii, 2017. Under the assumption
of a constant treatment effect τ, for all treatment assignments π1, π2 such that
cluster k is assigned to treatment under π1 but to control under π2:
rkiπ1 = rkiπ2 + τ.
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We define rCki (rTki) to be the potential outcome for participant i under any assign-
ment that that sets cluster k to control (treatment).
To determine a confidence interval for the treatment effect τ, construct hypothe-
sis tests for
H0 : τ = τ0
over a grid of potential values τ0. For each value of τ0, recompute the difference-in-
differences statistic under the null hypothesis H0 : τ = τ0.
a. For each cluster assigned to the control arm, {k : Zk = 0}, the nk dimensional
vector of potential responses (change scores from baseline to followup) rτ0Ck
under the control is simply their vector of observed changes Rk.
b. For clusters assigned to the intervention arm, {k′ : Zk′ = 1}, the nk′ dimen-
sional vector of potential responses (change scores from baseline to followup)
rτ0Ck′ under the control is
rτ0Ck′ = Rk′ − τ1,
where 1 is an nk′ dimensional vector of 1’s.
c. Letting rτ0C be the vector of potential outcomes for all patients, calculate the
residuals after adjusting for baseline characteristics using the model described
in (4), and denote the residuals by:
eτ0 := g(X, rτ0C ).
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d. Repeat steps (5)-(8) using eτ0 in place of the observed vector of patient spe-
cific residuals e0 to determine a difference-in-differences statistic Ŝτ0 and
associated p-value.
e. The set of values τ0 under which one would fail to reject the null hypothesis
H0 : τ = τ0 in a two-sided 0.05-level test forms the 95% confidence interval
for the treatment effect τ under a hypothesis of a constant treatment effect τ0
for every individual.
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We have presented the analysis of two types of randomized control trials: a col-
lection of clinical trials assessing the use of pre-exposure prophylaxis for HIV
prevention and a cluster randomized trial evaluating the use of a community
engagement intervention designed to improve health outcomes. Our analyses
addressed a range of statistical challenges, including sparse data and rare out-
comes, certain data available for only a subset of study participants through nested
substudies, low (and at times uncertain) levels of adherence, and small numbers of
and interference between study units. Although the designs and substantive areas
of the trials differ, the different applications offer a number of parallels.
A substantial challenge in both projects is uncertainty in the level of exposure
each study participant received to their assigned treatment. In the PrEP trials,
participant adherence to was highly varied and was estimated using unreliable
measures (Abaasa et al., 2017). We used participant concentration levels estimated
from a pharmacokinetic model to better account for variability in dosing than raw
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concentration measurements could. An important extension of the PrEP project
will be to quantify how the uncertainty in the average concentrations impacts
our estimates of the protective effect of different levels of PrEP concentration.
In Chapter 3, we discussed a potential Bayesian framework for propagating the
prediction uncertainty from PK modeling to the second stage modeling of HIV
risk.
In the Baltimore CONNECT study, we did not know if the patients from whom
we had health care utilization data actually visited their local community based
organization. To address this challenge, we inferred the causal effect of assigning
one’s geographically closest CBO to the intervention on hospital utilization among
Medicare and Medicaid recipients in Baltimore. It would be preferable, however,
to analyze the effect of the intervention on hospital patients known to be served by
the CBOs. Developing a such a study design while maintaining both client and
patient confidentiality remains an open challenge.
A natural extension of both projects is to consider future trial design. As
mentioned in Chapter 1, there are a number of ongoing PrEP clinical trials. The
continued development of different PrEP formulations and importance of deter-
mining effective dosing strategies for a wide range of at-risk populations motivates
future trial development. Cutrell et al. (2017) discuss a number of considerations
and propose innovations for future trial design, in particular for non-inferiority and
superiority studies that compare new PrEP formulations to oral TDF/FTC. PrEP
implementation and delivery will also guide future trial design (Norton, Larson,
and Dearing, 2013; Baeten et al., 2013; Krakower et al., 2014; Mayer, Krakower,
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and Boswell, 2016). Coordination of resources and care between community and
clinical settings, as was the goal of Baltimore CONNECT, will likely feature heavily
in this work (Norton, Larson, and Dearing, 2013). Lessons from the Baltimore
CONNECT study may be beneficial in considering future trials that assess the
utility of leveraging existing social structures to implement PrEP for reducing HIV
infection.
Additionally, the Baltimore CONNECT partnership has since expanded to form
a network of nonprofits as a 501(c)(3) organization. Evaluation of the sustain-
ability of this network and its broader impact will motivate future study design
considerations.
Although this dissertation centers around statistical challenges methods in the
analysis of randomized control trials, in both of the applications we presented,
the complex social structures, needs, and interactions within these trials affect our
analyses. Integrating qualitative research through mixed methods for developing
and supplementing analyses is integral. In PrEP clinical trials, a number of factors,
such as trust in one’s partner, power dynamics in relationships, and social stigma,
affected both levels and accurate reporting of adherence (Ware et al., 2012; Van
der Straten et al., 2014; Straten et al., 2016). These factors were largely discerned
from interviews and discussions with study participants. Carballo-Diéguez et al.
(2017) discuss the effectiveness of a mixed methods approach to determining study
participant adherence. The following point made by Van der Straten et al. (2014) in
their analysis of a qualitative, supplementary study to the VOICE trial is critical:
Clinical trials are more than biomedical enterprises to test new drugs:
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they are social phenomena that create new social relations within the
household, the clinical trial setting, the local community, and translo-
cally with donor organizations and research agencies. These social
relations will shape and reshape local knowledge and the meaning of
participation in clinical trials and of testing experimental drugs. Ad-
ditionally, drugs are not mere active pharmaceutical ingredients, they
are social innovations that require commensurability within the lives of
their adopters and their social network [51,52], whether the adopters
are clinical trial participants or real world users. (Van der Straten et al.,
2014)
A similar point is expressed by Ibe et al. (2018) in discussing the framework to
the Baltimore CONNECT study that Ibe et al. (2018)
...the structure of the trial itself stimulated knowledge brokerage at
multiple levels. This positioned the study’s stakeholders to emerge
as community knowledge brokers and placed them squarely on the
pathway of global innovation flow. (Ibe et al., 2018)
These studies not only evaluate the impact of exposures and interventions but also
directly impact the populations they study. The analysis of randomized control
trials exists within a broad public health framework. To be impactful, our statistical
analyses should not be conducted in isolation, but rather consider the complicated
social structures and interactions in play.
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